Login to Your Account



In The Clinic NEWS

Amgen Inc. said a regimen of Kyprolis, melphalan and prednisone failed to extend median progression-free survival for newly diagnosed multiple myeloma patients beyond what's delivered by a similar regimen anchored instead by Takeda Oncology Co.'s Velcade.

After Monday's market close, Kite Pharma Inc. reported top-line results from a pre-planned interim analysis of the phase II portion of its ZUMA-1 trial.

Two established biopharma execs and a repurposed drug with a wealth of safety data and promising efficacy in a randomized study netted startup Orbus Therapeutics Inc. $32.5 million in series A funding last year.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: